The near-term growth constraints stem from the operational lag required to restock Chinese distribution pipelines and win back consumers who pivoted to rival brands during the peak shortage window. The disruption—caused by a convergence of air and sea cargo crunches, manufacturing backlogs at primary processing partner Synlait, and heightened Chinese border inspection protocols—drained field inventory during April and May. Management confirmed that retail offtake is currently running at roughly 40 percent of pre-disruption levels, with a full commercial return to normalized run rates projected by the close of FY27.

On profitability, the company anticipates an EBITDA margin of approximately 15 percent for FY27, down from its normalized baseline of 16.6 percent in FY25. Chief Financial Officer David Muscat explained that the margin contraction is primarily driven by gross margin headwinds rather than excessive administrative or promotional overhead. Higher raw milk input costs, firming dairy ingredient prices (particularly whey and lactose fractions), and product mix variations will weigh on operating margins until processing throughput scales to target volumes.

A central operational catalyst for the second half of FY27 is the manufacturing transition to the newly acquired Pōkeno facility in the North Island. After recording an initial EBITDA loss of $23.2 million at Pōkeno during its integration phase in FY26, a2 Milk expects the manufacturing site to achieve EBITDA breakeven during FY27. Crucially, the plant will directly produce two new China-label IMF registrations scheduled for market launch in the first half of the financial year, substantially increasing asset utilization and insulating the business from third-party supply vulnerabilities.